Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

PONATINIB for Neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 21 adverse event reports in the FDA FAERS database where PONATINIB was used for Neoplasm malignant.

Most Reported Side Effects for PONATINIB

Side Effect Reports % Deaths Hosp.
Death 1,735 17.3% 1,735 548
Off label use 1,071 10.7% 287 488
Product dose omission issue 817 8.2% 159 481
Fatigue 687 6.9% 131 385
Rash 639 6.4% 122 299
Headache 553 5.5% 78 293
Pyrexia 542 5.4% 129 406
Nausea 466 4.7% 62 265
Hospitalisation 459 4.6% 70 458
Constipation 435 4.4% 74 253
Drug ineffective 406 4.1% 82 157
Arthralgia 386 3.9% 49 206
Dry skin 381 3.8% 69 205
Platelet count decreased 379 3.8% 108 224
Hypertension 370 3.7% 52 177

Other Indications for PONATINIB

Chronic myeloid leukaemia (4,723) Acute lymphocytic leukaemia (2,408) Product used for unknown indication (855) Philadelphia positive acute lymphocytic leukaemia (487) Acute myeloid leukaemia (284) Acute lymphocytic leukaemia recurrent (195) Acute lymphocytic leukaemia (in remission) (116) Chronic myeloid leukaemia transformation (114) Myeloid leukaemia (110) Chronic myeloid leukaemia (in remission) (90)

Other Drugs Used for Neoplasm malignant

PALBOCICLIB (1,996) CAPECITABINE (1,493) PEMBROLIZUMAB (1,135) PACLITAXEL (984) CARBOPLATIN (977) NIVOLUMAB (947) OXALIPLATIN (823) PAZOPANIB (716) CYCLOPHOSPHAMIDE (685) FLUOROURACIL (676)

Related Pages

PONATINIB Full Profile All Neoplasm malignant Drugs PONATINIB Demographics PONATINIB Timeline